pyridoxamine has been researched along with Diabetes Mellitus, Type 2 in 13 studies
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "It appears that pyridoxamine ameliorated lipid peroxidation and insulin resistance in KK-A(y)/Ta mice." | 3.75 | Pleiotropic effect of pyridoxamine on diabetic complications via CD36 expression in KK-Ay/Ta mice. ( Gohda, T; Hagiwara, S; Horikoshi, S; Ishikawa, Y; Murakoshi, M; Ohara, I; Tanimoto, M; Tomino, Y; Toyoda, H, 2009) |
| "The pyridoxamine pilot study was designed to test entry criteria and outcomes." | 2.80 | Pyridoxamine dihydrochloride in diabetic nephropathy (PIONEER-CSG-17): lessons learned from a pilot study. ( Broome, BR; Dwyer, JP; Fox, JW; Greco, BA; Greene, LE; Lewis, JB; Packham, D; Peterson, R; Sika, M; Umanath, K, 2015) |
| "Treatments of diabetic nephropathy (DN) delay the onset of end-stage renal disease." | 2.73 | Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. ( Bolton, WK; Degenhardt, TP; Khalifah, RG; McGill, JB; Schotzinger, RJ; Williams, ME, 2007) |
| "Levels of blood glycation and disc degeneration were investigated." | 1.56 | Advanced Glycation End Product Inhibitor Pyridoxamine Attenuates IVD Degeneration in Type 2 Diabetic Rats. ( Avalos, P; Bae, HW; Glaeser, JD; Ju, D; Kaneda, G; Kanim, LEA; Metzger, MF; Salehi, K; Sheyn, D; Stefanovic, T; Stephan, S; Tawackoli, W; Yang, JH, 2020) |
| " Metabolic profile, NO bioavailability and vascular oxidative stress, AGE and Nrf2 levels were also assessed." | 1.46 | The Sulforaphane and pyridoxamine supplementation normalize endothelial dysfunction associated with type 2 diabetes. ( Crisóstomo, J; Fernandes, R; Pereira, A; Seiça, RM; Sena, CM, 2017) |
| "Pyridoxamine treatment, as single therapy, decreased the progression of albuminuria and glomerular lesions." | 1.33 | Combined AGE inhibition and ACEi decreases the progression of established diabetic nephropathy in B6 db/db mice. ( Berho, M; Elliot, SJ; Plati, AR; Potier, M; Striker, GE; Striker, LJ; Zeng, YJ; Zheng, F, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 7 (53.85) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Glaeser, JD | 1 |
| Ju, D | 1 |
| Tawackoli, W | 1 |
| Yang, JH | 1 |
| Salehi, K | 1 |
| Stefanovic, T | 1 |
| Kanim, LEA | 1 |
| Avalos, P | 1 |
| Kaneda, G | 1 |
| Stephan, S | 1 |
| Metzger, MF | 1 |
| Bae, HW | 1 |
| Sheyn, D | 1 |
| Jiang, M | 1 |
| Yakupu, A | 1 |
| Guan, H | 1 |
| Dong, J | 1 |
| Liu, Y | 1 |
| Song, F | 1 |
| Tang, J | 1 |
| Tian, M | 1 |
| Niu, Y | 1 |
| Lu, S | 1 |
| Pereira, A | 1 |
| Fernandes, R | 1 |
| Crisóstomo, J | 1 |
| Seiça, RM | 1 |
| Sena, CM | 1 |
| Alicic, RZ | 1 |
| Tuttle, KR | 1 |
| Dwyer, JP | 1 |
| Greco, BA | 1 |
| Umanath, K | 1 |
| Packham, D | 1 |
| Fox, JW | 1 |
| Peterson, R | 1 |
| Broome, BR | 1 |
| Greene, LE | 1 |
| Sika, M | 1 |
| Lewis, JB | 2 |
| Ren, X | 1 |
| Sun, H | 1 |
| Zhang, C | 1 |
| Li, C | 1 |
| Wang, J | 1 |
| Shen, J | 1 |
| Yu, D | 1 |
| Kong, L | 1 |
| Murakoshi, M | 2 |
| Tanimoto, M | 2 |
| Gohda, T | 2 |
| Hagiwara, S | 2 |
| Ohara, I | 1 |
| Toyoda, H | 1 |
| Ishikawa, Y | 1 |
| Horikoshi, S | 2 |
| Tomino, Y | 2 |
| Unoki-Kubota, H | 1 |
| Yamagishi, S | 1 |
| Takeuchi, M | 1 |
| Bujo, H | 1 |
| Saito, Y | 1 |
| Lewis, EJ | 1 |
| Greene, T | 1 |
| Spitalewiz, S | 1 |
| Blumenthal, S | 1 |
| Berl, T | 1 |
| Hunsicker, LG | 1 |
| Pohl, MA | 1 |
| Rohde, RD | 1 |
| Raz, I | 1 |
| Yerushalmy, Y | 1 |
| Yagil, Y | 1 |
| Herskovits, T | 1 |
| Atkins, RC | 1 |
| Reutens, AT | 1 |
| Packham, DK | 1 |
| Engelen, L | 1 |
| Stehouwer, CD | 1 |
| Schalkwijk, CG | 1 |
| Zheng, F | 1 |
| Zeng, YJ | 1 |
| Plati, AR | 1 |
| Elliot, SJ | 1 |
| Berho, M | 1 |
| Potier, M | 1 |
| Striker, LJ | 1 |
| Striker, GE | 1 |
| Kaneko, S | 1 |
| Aoki, T | 1 |
| Yamada, K | 1 |
| Ito, T | 1 |
| Matsumoto, M | 1 |
| Williams, ME | 1 |
| Bolton, WK | 1 |
| Khalifah, RG | 1 |
| Degenhardt, TP | 1 |
| Schotzinger, RJ | 1 |
| McGill, JB | 1 |
2 reviews available for pyridoxamine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Novel therapies for diabetic kidney disease.
Topics: Acetylcysteine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antihypertensive Agents; | 2014 |
Current therapeutic interventions in the glycation pathway: evidence from clinical studies.
Topics: Animals; Atherosclerosis; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathie | 2013 |
3 trials available for pyridoxamine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Pyridoxamine dihydrochloride in diabetic nephropathy (PIONEER-CSG-17): lessons learned from a pilot study.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Antioxidants; Creatinine; D | 2015 |
Pyridorin in type 2 diabetic nephropathy.
Topics: Aged; Creatinine; Cystatin C; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method | 2012 |
Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy.
Topics: Adolescent; Adult; Aged; Creatine; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Ne | 2007 |
8 other studies available for pyridoxamine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Advanced Glycation End Product Inhibitor Pyridoxamine Attenuates IVD Degeneration in Type 2 Diabetic Rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; | 2020 |
Pyridoxamine ameliorates methylglyoxal-induced macrophage dysfunction to facilitate tissue repair in diabetic wounds.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Macrophages; Mice; Pyridoxamine | 2022 |
The Sulforaphane and pyridoxamine supplementation normalize endothelial dysfunction associated with type 2 diabetes.
Topics: Animals; Aorta; Diabetes Mellitus, Type 2; Dietary Supplements; Disease Models, Animal; Endothelium; | 2017 |
Protective function of pyridoxamine on retinal photoreceptor cells via activation of the p‑Erk1/2/Nrf2/Trx/ASK1 signalling pathway in diabetic mice.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease M | 2016 |
Pleiotropic effect of pyridoxamine on diabetic complications via CD36 expression in KK-Ay/Ta mice.
Topics: Adipose Tissue; Animals; CD36 Antigens; Diabetes Complications; Diabetes Mellitus, Experimental; Dia | 2009 |
Pyridoxamine, an inhibitor of advanced glycation end product (AGE) formation ameliorates insulin resistance in obese, type 2 diabetic mice.
Topics: Animals; Diabetes Mellitus, Type 2; Glycation End Products, Advanced; Insulin Resistance; Male; Mice | 2010 |
Combined AGE inhibition and ACEi decreases the progression of established diabetic nephropathy in B6 db/db mice.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzazepine | 2006 |
Effect of pyridoxamine (K-163), an inhibitor of advanced glycation end products, on type 2 diabetic nephropathy in KK-A(y)/Ta mice.
Topics: Animals; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dose-Response Relationship, Drug; Glycat | 2007 |